Patents by Inventor Patrick Baeuerle

Patrick Baeuerle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20200283490
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • ACTIVATABLE INTERLEUKIN 12 POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20200283489
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20200207828
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: June 10, 2019
    Publication date: July 2, 2020
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Activatable interleukin-2 polypeptides
    Patent number: 10696724
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: June 30, 2020
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • Activatable interleukin 12 polypeptides
    Patent number: 10696723
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: June 30, 2020
    Assignee: Werewolf Therapeutics, Inc.
    Inventors: William Winston, Daniel Hicklin, Vinay Bhaskar, Luke Evnin, Patrick Baeuerle, Jose Andres Salmeron Garcia, Heather Brodkin, Cynthia Seidel-Dugan
  • INDUCIBLE MONOVALENT ANTIGEN BINDING PROTEIN
    Publication number: 20200148771
    Abstract: Disclosed herein are inducible monovalent target-binding proteins which are activated upon protease cleavage. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Application
    Filed: February 28, 2018
    Publication date: May 14, 2020
    Inventors: Patrick BAEUERLE, Holger WESCHE
  • ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20200040052
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: June 11, 2019
    Publication date: February 6, 2020
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN
  • ACTIVATABLE INTERLEUKIN 12 POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20190367576
    Abstract: The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
    Type: Application
    Filed: June 11, 2019
    Publication date: December 5, 2019
    Inventors: William WINSTON, Daniel HICKLIN, Vinay BHASKAR, Luke EVNIN, Patrick BAEUERLE, Jose Andres SALMERON GARCIA, Heather BRODKIN
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 10442849
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: October 15, 2019
    Assignee: TCR2 THERABEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20190276540
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFP, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: November 22, 2017
    Publication date: September 12, 2019
    Inventors: Patrick BAEUERLE, Robert HOFMEISTER
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20190256571
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: August 2, 2017
    Publication date: August 22, 2019
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • INNATE IMMUNE CELL TRISPECIFIC BINDING PROTEINS AND METHODS OF USE
    Publication number: 20190225702
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to innate immune cells, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 13, 2017
    Publication date: July 25, 2019
    Inventors: Patrick BAEUERLE, Luke EVNIN, Jeanmarie GUENOT, Holger WESCHE
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 10358473
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 23, 2019
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 10358474
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 23, 2019
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20190177694
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 13, 2019
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 10208285
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: February 19, 2019
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20180251514
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 6, 2018
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20180244747
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
  • BISPECIFIC-FC MOLECULES
    Publication number: 20180230220
    Abstract: Described herein is a bispecific molecule containing an Fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules.
    Type: Application
    Filed: February 1, 2018
    Publication date: August 16, 2018
    Inventors: Luis G. Borges, Patrick A. Baeuerle, Wei Yan, Mark L. Michaels
  • COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
    Publication number: 20180230429
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: February 5, 2018
    Publication date: August 16, 2018
    Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER